Tuesday, August 4, 2026

Fw: Ref.: (LML) Infolep monthly overview of new publications on leprosy. July, 2026


 

Leprosy Mailing List –  August 4,  2026

 

Ref.:  (LML) Infolep monthly overview of new publications on leprosy. July, 2026

From: Elizabeth Talatu Williams, Amsterdam, the Netherlands

____________________________________________________________________________




Dear colleagues,

We are pleased to share the July 2026 edition of the Infolep newsletter, featuring recent publications, case reports, and global updates from the leprosy field.

Infolep announces the publication of the Prevention of Leprosy: Single-Dose Rifampicin Post-Exposure Prophylaxis (SDR-PEP) Toolkit, developed by the GPZL SDR-PEP Sub-group. This toolkit brings together materials, tools, and key documents developed based on experience gained from projects and programmes implemented across diverse leprosy-endemic settings and contexts.
Access the toolkit here.

This month's featured articles explore the psychosocial impact of disability and stigma among persons affected by leprosy and lymphatic filariasis, healthcare access and community knowledge in Malawi, and active case detection among incarcerated populations in Brazil. We also feature several case reports highlighting diverse clinical presentations of leprosy and the continued importance of early diagnosis.

It also includes new research on innovative approaches to leprosy control, including teleinterconsultation for disability surveillance, the development and validation of a chatbot for managing leprosy lesions, advances in biomarker discovery, and studies on disease transmission, maternal and childhood leprosy, and programme implementation across endemic settings.

Just two months to go until the 17th Annual NTD NGO Network (NNN) Conference, taking place in Kigali, Rwanda, from 29 September to 1 October 2026. Registrations are still open, don't miss the opportunity to join global partners working to eliminate neglected tropical diseases.

Stay tuned to Infolep for more updates, resources, news, and tools that support your work in leprosy.

Warm regards,
Elizabeth Talatu Williams

www.leprosy-information.org
info@infolep.org
 




 



 



Featured Research Spotlight

The psychosocial impact of disability and stigma among persons affected by leprosy and lymphatic filariasis in India
van Wijk R, Agarwal A, Nayak P, et al. PLOS mental health. 2026; 3 (7): 1 – 16


Beyond elimination: Assessing healthcare access, knowledge, attitudes, and practices regarding leprosy among communities in Lilongwe and Balaka districts of Malawi
Singano N, Lubanga A, Kacheyo J, et al. PLoS neglected tropical diseases. 2026; 20 (7): 1 - 15.


Hidden burden of leprosy in incarcerated populations in northeast Brazil: active case detection and serological assessment
de Lucena TS, Galani LC, Barbosa LD, et al. European Journal of Clinical Microbiology & Infectious Diseases. Springer Science and Business Media LLC. 2026.

 



 



 



Other New Publications


Feel free to contact us to receive full-text versions if these cannot be found through the Infolep portal.

 



Immune Dysregulation and Community Health Factors in Maternal and Childhood Leprosy: A Partial Least Squares-Structural Equation Modelling Study
Prakoeswa FRS, Endaryanto A, Prakoeswa CRS. Infection & Chemotherapy. XMLink. 2026; 58 (2): 224.


Temporal and spatial patterns of Leprosy in Uganda, 2020-2024: A nationwide surveillance analysis
Abbo G, Migisha R, Mfitundinda E, et al. PLoS neglected tropical diseases. 2026; 20 (7): 1 - 14. 


Teleinterconsultation as a strategy to support surveillance of physical disability in leprosy in the state of Maranhão, Brazil
Neves ACFB, Matos SOV, Pereira VF, et al. Ciência & Saúde Coletiva. FapUNIFESP (SciELO). 2026; 31 (5): 1 - 8. 


Development and validation of a chatbot for managing leprosy lesions
Martins RMG, Alves DDA, Alves SAA, et al. Ciência & Saúde Coletiva. FapUNIFESP (SciELO). 2026; 31 (5): 1 - 11.


Mass Spectrometry-Based Metabolomics in Formalin-Fixed Paraffin-Embedded Skin Biopsies Identifies Potential Candidate Biomarkers for Leprosy Progression Across the Ridley–Jopling Clinical Spectrum
Pereira NV, Dornelas BDC, Costa WVTD, et al. Microorganisms. MDPI AG. 2026; 14 (7): 1 - 21. 

 


A retrospective review of leprosy diagnosed histopathologically from skin biopsy specimens in central South Africa
van Wyk R, le Grange D, Budding L. Southern African journal of infectious diseases. 2026; 41 (1): 1 - 9.


Transmission Interruption of Leprosy in the Philippines: An Update on the Current Program Priorities and Interventions
Fatunmbi BS, Taruc AY, Sanikullah KH, et al. Tropical Medicine and Infectious Disease. MDPI AG. 2026; 11 (7) : 1 - 13.


Medical students’ self-perception about Leprosy at a university in the amazon region
Pinho Rodrigues VI, Coelho Yano K, Costa Quaresma T, et al. Revista Brasileira de Neurologia. Revista Brasileira de Neurologia. 2026; 62 (2): 1 - 6.


The Correlation Between Knowledge and Family Support for Self-Care of Leprosy Patients
Saleh NC, Armaijn L, Sakurawati A. Asian Journal of Engineering, Social and Health. Ridwan Institute. 2026; 5 (7): 727 - 734. 


Renal Involvement in Leprosy in the Multidrug Therapy Era: Current Evidence and Clinical Monitoring
de Oliveira K, Corrêa LMDA, Brandão LKV, et al. Current Tropical Medicine Reports. Springer Science and Business Media LLC. 2026; 13 (1): 1 - 13. 

 



 



 



Case Reports

A Six Year Old Boy with Lepromatous Leprosy: A Case Report Revealing an Unsolved Mystery
Sobhan S, Farook M. Mymensingh medical journal: MMJ. 2026; 35 (3): 959-964.


Oral Diagnosis of Lepromatous Leprosy in a Hyperendemic Region of Brazil
Rosa A, Alves M, Dorta R. Head and neck pathology. 2026.


Evidence of autochthonous transmission of leprosy, causing an outbreak in a family
Mansoori N, Farzaneh T, Sofizadeh A. Leprosy Review. Lepra. 2026; 97 (2): 1 - 5. 


Paucibacillary leprosy presenting as fibular neuropathy: A case of autochthonous zoonotic exposure in endemic Florida
Ruffing K. PLoS neglected tropical diseases. 2026; 20 (6): 1 - 5. 

 



 



Latest News

 


 



Early detection and leprosy-post exposure prophylaxis programme in Kaski [World Health Organization]


Cabinet clears amendment to remove 'leprosy' from Goa Children's Act [Times of India]


Scientists puzzled by rising leprosy in Florida [Florida Today]


Florida woman starts leprosy support group as state sees rise in cases [AOL]


Kano to enrol 6,000 TB, leprosy patients into healthcare scheme [Punch]

 


EDCTP Prizes 2027: applications are open [Global Health EDCTP3]


Strengthening capacity of frontline health workers for leprosy diagnosis and management [World Health Organization]


Govt targets 37,000 leprosy case detections to speed up elimination [Antara News]


J&K declares Leprosy a notifiable disease, hospitals directed to report cases [The News Now]


Chhattisgarh CM Vishnu Deo Sai visits leprosy ashram, hails it as 'true pilgrimage of humanity' [IndiaTV News]

 



 



Upcoming Events

 


 



Venue update — NNN Conference 2026

Location: Kigali, Rwanda
Date: 29 September – 1 October 2026

Theme: People, Systems, & Resilience: Adapting NTD Responses Through Holistic Approaches

The NNN Conference 2026 will now be held in Kigali, Rwanda. Dates remain unchanged. Following careful monitoring of the ongoing situation in the WHO Eastern Mediterranean region, NNN has taken the decision to relocate this year's conference. 

Registrations are currently open!

 


13th Edition of the EDCTP Forum

Location: Madrid, Spain
Date: 5 – 9 April, 2027

Over the past two decades, the biennial European & Developing Countries Clinical Trials Partnership (EDCTP) Forum has evolved to become a cornerstone event for global health research, bringing together leading voices advancing the fight against infectious diseases in sub-Saharan Africa. It showcases the latest scientific breakthroughs, highlights impactful capacity-building efforts, and creates a space for vibrant cross-regional collaboration.
 

 



 


 



 



Links

 



Info Hansen - An innovative hub for knowledge sharing about Hansen's Disease
 


ALLF - Official website of the Association des Léprologues de Langue Française
 


LML - Leprosy Mailing List - a free moderated email list that allows all persons interested in leprosy to share ideas, information, experiences and questions
 


InfoNTD - Information on cross-cutting issues in Neglected Tropical Diseases (NTDs)

 


ILEP newsletter archive


GPZL newsletter subscription


WHO Goodwill Ambassador's Leprosy Bulletin


Leprosy Review


Leprosy Review Repository (1928-2001)


Fontilles Revista de Leprología


Indian Journal of Leprosy


Hansenologia Internationalis


HARP -  Hansen's Disease Antimicrobial Resistance Profiles

 




GDPR & the Infolep newsletter

 
New EU data protection regulations came into force on 25 May 2018. We have been reviewing our practices with regards to the GDPR, including our
privacy statement and mailing list.

Infolep sends out monthly e-mails with an overview of recent publications on leprosy and related issues. The purpose of this activity is to keep subscribers up to date.

Infolep will only process the data we have (names, email addresses) for the purpose of sending you the newsletter. We take your security seriously and will never share your contact details with anyone else.

You can
update your preferences or unsubscribe from this list at any time.

 


 



____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com


--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/734a8fa1-1543-4b82-aa3c-eb959562cb00n%40googlegroups.com.

Monday, August 3, 2026

Fw: Ref.: (LML) Long-lasting adverse impact of chemoprophylaxis & what actually works

 

Leprosy Mailing List –   August 3,  2026

 

Ref.:  (LML) Long-lasting adverse impact of chemoprophylaxis & what actually works

From: Benedict Quao, Cape Coast, Ghana

____________________________________________________________________________

 

Dear colleagues,

 

Although the Leprosy Mailing List Blog is an open forum for sharing information among people working in the field of leprosy, and thus not set up for scientific discussions, we would like to encourage readers to critically evaluate the evidence supporting the conclusions on Single Dose Rifampicin (SDR) as Post-Exposure Prophylaxis (PEP) presented in this email from Dr. Joel Almeida. While novel hypotheses are an important part of scientific progress, they should be clearly distinguished from conclusions supported by robust experimental or epidemiological evidence. In Dr. Almeida's recent email, several statements are presented as established facts despite remaining speculative or not being supported by the cited literature.

 

Below are a few examples:

 

1. Interpretation of the PEP-Hans data

The comparison between former PEP-Hans municipalities and non-PEP municipalities cannot be interpreted as evidence that chemoprophylaxis increased the risk of multibacillary (MB) leprosy or grade 2 disability (G2D). There were 16 PEP-Hans municipalities, which were specifically selected based on their classification as priority municipalities for leprosy by Brazil’s MOH. Comparing these municipalities to an unspecified number of other non-priority areas for leprosy with much higher total annual new leprosy case numbers collectively, years later, introduces substantial selection bias. Moreover, there is no clear indication that the comparator (non-PEP) municipalities are of comparable endemicity, nor is it evident that the duration of data collection was equivalent between the intervention and comparison groups, further limiting the validity of the comparison.

 

In addition, the figures presented begin only one year before the implementation of PEP. This provides an inadequate baseline for assessing the impact of the intervention. A substantially longer pre-intervention period (e.g., at least 5–10 years) is necessary to establish the underlying epidemiological trends and determine whether any observed changes differ from the historical trajectory of these municipalities. In the absence of such an extended baseline period, the incidence data should, at minimum, be normalised, and municipalities with substantially divergent baseline incidence trends should be excluded from the comparison.

 

Furthermore, the proposed temporal relationship is biologically implausible. M. leprae is an extremely slow-growing pathogen, and leprosy usually develops only after a prolonged incubation period, typically over several years. Consequently, any intervention that genuinely altered the risk of developing MB disease would not be expected to produce an immediate increase in incident MB cases or disease prevalence within a municipality. Any claim that PEP rapidly increased MB disease would therefore require exceptionally strong epidemiological evidence, which is not provided here. It is also worth noting that between 2022 and 2024, contact tracing intensified substantially in PEP municipalities than in non-PEP municipalities, which could independently increase case detection and thereby inflate the apparent proportion of MB cases.

 

Demonstrating a detrimental effect of PEP would require analyses accounting for baseline incidence, surveillance intensity, demographic differences, and other potential confounders, including the COVID-19 impact. An ecological comparison alone cannot establish causality.

 

2. Interpretation of the STING/OASL study

The study by de Toledo-Pinto et al. (ref 3) demonstrated that viable intracellular M. leprae can activate the cGAS-STING-OASL pathway, thereby promoting bacterial survival by modulating autophagy. In fact, their paper explicitly stated that the mechanisms underlying the direction of response following infection are not clearly understood, with the mycobacterial burden presented during infection being the most likely determinant – i.e. a low mycobacterial infective burden is more likely to result in autophagy and control of the infection, and vice versa. Furthermore, it did not investigate the effects of rifampicin-killed bacilli or demonstrate that bacterial debris generated by chemoprophylaxis produces prolonged suppression of macrophage function. Extending these findings to conclude that chemoprophylaxis "disarms" macrophages is therefore unsupported.

 

 

3. Persistence of bacterial debris

The statement that bacterial debris persists beyond the duration of chemoprophylaxis and continues to suppress macrophage function is presented without supporting evidence. This would require experimental demonstration of prolonged persistence of bacillary components together with sustained impairment of macrophage antimicrobial responses. To date, such evidence has not been demonstrated.

 

4. Emergence of "high-virulence" bacilli

The cited work on mycobacterial pole elongation (ref 4) describes normal bacterial growth dynamics. It does not demonstrate that antimicrobial exposure generates phenotypically more virulent M. leprae, nor that surviving bacilli express increased virulence factors following chemoprophylaxis. No experimental, transcriptomic, or genomic evidence currently supports this conclusion.

 

5. Linking these mechanisms to increased MB disease and disability

The proposed sequence of events (chemoprophylaxis kills bacilli, bacterial debris suppresses macrophages, surviving bacilli become more virulent, leading to increased MB disease and G2D) is entirely hypothetical. None of the intermediate steps are supported by the cited references. While this may represent an interesting biological hypothesis worthy of investigation, it should not be presented as an established mechanism. Public health recommendations should be based on robust experimental and epidemiological evidence, not on speculative mechanistic models that have yet to be validated.

 

6. Expected effects of chemoprophylaxis

Clinical trials have consistently shown that chemoprophylaxis partially reduces the risk of developing leprosy. Limited efficacy should not be interpreted as evidence of harm.

 

7. Asymptomatic "high shedders" as the main reservoir of transmission

Dr. Almeida further attributes the marked decline in new MB cases in São Luís, Maranhão to the identification and treatment of these presumed "high shedders." However, this conclusion is not supported by the evidence presented.

 

(A) A reduction in case numbers may result from multiple factors, including intensified case detection, earlier diagnosis, prompt treatment of clinically affected individuals, improved contact tracing, changes in surveillance practices, and broader public health interventions. Without an appropriate epidemiological analysis accounting for these potential confounders, it is not possible to attribute the observed decline specifically to the treatment of asymptomatic individuals.

 

(B) More fundamentally, the existence of a population of asymptomatic individuals who consistently shed large quantities of viable M. leprae and represent a major driver of transmission has not been demonstrated.

Molecular studies have detected M. leprae DNA (and in some cases RNA1) in nasal swabs from asymptomatic individuals2, but there is currently no convincing evidence that these individuals represent clinically silent lepromatous disease, that they consistently shed viable bacilli, or that they account for a substantial proportion of transmission. Their prevalence, duration of carriage, infectiousness, and public health significance remain unknown and is not reported in any publication cited by Dr. Almeida.

In this context, the email also states that Maranhão has implemented semi-quantitative mLAMP to identify individuals shedding M. leprae. However, no supporting reference or validation study is provided.

 

(C) More importantly, if the hypothesis is based on the detection of M. leprae DNA alone, the conclusion is not justified. Detection of bacterial DNA in nasal secretions demonstrates only that bacterial genetic material is present; it does not establish that intact, viable bacilli are being shed. DNA may persist after bacterial death or originate from non-viable organisms. In contrast, detection of bacterial RNA provides substantially stronger evidence for viable, metabolically active bacilli and is currently the most appropriate molecular approach for assessing bacterial viability. Therefore, conclusions regarding infectiousness or transmission cannot be based solely on DNA detection.

 

In summary, the interpretation presented does not consistently follow the scientific process by which observations are critically analysed before causal conclusions are drawn. Scientific reasoning requires that hypotheses be tested against the available evidence, that alternative explanations and potential confounding factors be considered, and that conclusions remain proportional to the strength of the supporting data. In several instances, hypotheses are presented as established mechanisms and causal relationships without sufficient experimental or epidemiological evidence to support those interpretations.

 

 

 

On behalf of the ILEP Technical Commission,

 

 

Benedict Quao

 

 

References

1.    Beissner M, Woestemeier A, Saar M, Badziklou K, Maman I, Amedifou C, et al. Development of a combined RLEP/16S rRNA (RT) qPCR assay for the detection of viable M. leprae from nasal swab samples. BMC Infect Dis 2019;19:753. https://doi.org/10.1186/s12879-019-4349-9.

2.    Gama RS, Gomides TAR, Gama CFM, Moreira SJM, de Neves Manta FS, de Oliveira LBP, et al. High frequency of M. leprae DNA detection in asymptomatic household contacts. BMC Infect Dis 2018;18:153. https://doi.org/10.1186/s12879-018-3056-2.

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com

 


--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/e9e5c686-2155-4a49-a5d7-8e8d48d007b8n%40googlegroups.com.

Wednesday, July 29, 2026

Fw: Ref.: (LML) Sensitivity of mLAMP


 

Leprosy Mailing List –  July 29,  2026

 

Ref.:  (LML) Sensitivity of mLAMP

From: Joel Almeida, Mumbai, India

____________________________________________________________________________

 

Dear Pieter and colleagues,

mLAMP can be used in two distinct ways, to simultaneously detect M. leprae and/or M. lepromatosis: 

a) in total population surveys using nasal swabs and mLAMP with a relatively quick cut-off  time (few minutes) to distinguish between high-shedders and casual carriers of trivial numbers of bacilli.

b) to aid clinical diagnosis using skin smears or biopsies with a long cut-off time (e.g. 1 hour) to permit maximum sensitivity.

Wang et al (2025) wrote: "The M. leprae HiFi-LAMP assay has high specificity and sensitivity with a limit of detection (LOD) of 43 copies/25 μL reaction. Both sensitivity and specificity of the HiFi-LAMP assay were 100% for 130 purified DNA from nasal and oral samples."
https://doi.org/10.1016/j.ijid.2025.107835
> 43 copies of RLEP are contained in only 2 bacilli.

Persons with lived experience need not explore the underlying biology. mLAMP kits that provide a clear colour change (by using dyes) would seem ideal for field use. For detecting cryptic asymptomatic LL high-shedders, the amplification kinetics at that template concentration are dominated by near-immediate primer saturation (relatively rapid colour change when dyes are used).

With all sincerity,

Joel Almeida



PS 

Missing small numbers of bacilli in someone with PB HD or subclinical infection is not necessarily disastrous, because many of such persons resolve on their own without ever becoming high-shedders of bacilli and they are at low risk of visible deformities compared to MB HD. There is no need to target them with fear or prejudice. Good clinical examination is helpful, together with investigations (that can include mLAMP with plenty of time allowed for maximum sensitivity).

Missing even a single high-shedding LL is disastrous not just for the individual, who can suffer visible deformity before diagnosis, but also for the population. Missing such a person allows the floodgates of infection to remain open. This produces a continuous stream of secondary cases at risk of deformity, including further cryptic asymptomatic LL.

Davey and Rees (1974 Lepr Rev 45(2):121-34) showed that cryptic asymptomatic and unprotected LL HD cases can shed as many as 10^7 viable bacilli/day (or even per nose blow). By contrast, zero of 208 unprotected BL HD cases showed a bacillary index (BI) of 5+ or 6+ in nasal smears, whereas many unprotected LL HD cases did so. BB, BT and TT cases are even less likely than BL HD to shed many bacilli. Unprotected LL HD seems overwhelmingly important to transmission, and to reseeding the surroundings.

Further, subclinical infection is widespread in endemic areas (Godal and Negassi 1973 BMJ 3 (5880): 557-559) yet in many endemic areas <1 in 10k population/year are newly detected with signs of HD. If 50% of all persons in an endemic area have ever been infected, then over a 70 year lifespan an asymptomatic ever-infected contact has >98% probability of safely self-limiting or eliminating the bacilli - without showing signs, sequelae or onward transmission. Natural macrophage defences seem important. Most of the genomic polymorphisms known to modify  the risk of HD, and LL HD, are related to macrophage function. (Mi, Liu, Zhang 2024 hLife 2:6–17).

Reinfection, especially of persons with genomes predisposing to LL type of HD, is another important challenge. (Uaska Sartori et al, 2020 Sci Rep 10, 1284, Goncalves et al Gonçalves et al (2019) https://doi.org/10.1186/s12879-019-4100-6, Stefani et al (2017)  https://doi.org/10.1371/journal.pntd.0005598).

This is why ending HD transmission requires nasal swabs to be taken from ALL asymptomatics in a cluster. Only then can all the unique sources of concentrated viable bacilli in a cluster, undetected and unprotected LL HD high-shedders, be found and protected. They receive full free treatment and regular check-ups to protect their nerves. Given all that, extending and expanding primary health care via persons with lived experience and basic training is extremely helpful for rapidly reducing transmission, monitoring muscle weakness, encouraging completion of treatment and more.

 

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com

 


--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/14414c94-20d0-4975-bf2d-498a16b00429n%40googlegroups.com.

Monday, July 27, 2026

Fw: Ref.: (LML) Reflecting on 2025: Progress, Partnership, and a Sustainable Future


 

 

Leprosy Mailing List –  July 27,  2026

 

Ref.:  (LML) Reflecting on 2025: Progress, Partnership, and a Sustainable Future

From: LRI, Amsterdam, the Netherlands

____________________________________________________________________________

 Dear colleagues,


 

 




Reflecting on 2025: Progress, Partnership, and a Sustainable Future
The Leprosy Research Initiative (LRI) continues to support its mission of promoting and funding high-quality research, translating evidence into policy and practice, and strengthening research capacity in endemic countries. Together with our partners, researchers, and stakeholders, we remain united by a shared vision: a world free from leprosy.

As we reflect on 2025, we do so with both gratitude and determination. Throughout the year, we built on LRI’s strong foundation by advancing innovative research, strengthening research capacity, fostering collaboration, and preparing for future opportunities and challenges.

One of the highlights of the year was the launch of 10 new research projects, alongside the awarding of six new grants through two competitive grant cycles. These included three grants under the Research Capacity Strengthening programme and three grants through the RESILIENTD programme, funded by the Anesvad Foundation, which focuses on addressing the social determinants of skin Neglected Tropical Diseases (NTDs) in Sub-Saharan Africa.

Learn more about these grants:

Collaboration and knowledge sharing remained central to our work. The 10th LRI Spring Meeting brought together nearly 200 researchers and stakeholders from around the world, reflecting the growing engagement and strength of the global leprosy research community.

A significant milestone this year was the completion of LRI’s second external evaluation. The findings confirmed the continued relevance of our work while providing valuable recommendations to guide our future development. Building on these insights, we initiated the development of LRI’s first Multi-Annual Strategic Plan and began updating our research priorities to ensure our efforts remain focused, responsive, and impactful.

At a time when financial constraints across the global health and research sectors require thoughtful planning, LRI is adapting to ensure long-term sustainability. Beginning in 2026, we will adopt a biennial grant cycle model, alternating between flagship research calls and capacity-strengthening calls. This predictable framework will enable LRI to continue supporting research excellence while investing in future research leaders.

As we look ahead to 2026, we do so with a clear strategy, a focused mission, and confidence in the power of research to contribute to a world free of leprosy.

We extend our sincere thanks to our partners, committee members, researchers, donors, and the wider leprosy research community. Your commitment, expertise, and collaboration make our work possible and strengthen our collective impact.

Interested in learning more? Read the full LRI Annual Report 2025 to explore our achievements, impact, and future priorities.

 

Warm regards

 

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com


--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/84fb402d-bbdb-4c16-9a37-2ba7137de6adn%40googlegroups.com.

Fw: Ref: (LML) LAMP: a breakthrough


 

Leprosy Mailing List –  July 27,  2026

 

Ref.:  (LML) LAMP: a breakthrough

From: Joel Almeida, Mumbai, the Netherlands

____________________________________________________________________________

 

Dear Pieter and colleagues,

LAMP was invented in 2000. (1) It can be used for a wide range of pathogens (not just M. leprae or M. lepromatosis or leishmania etc (2) but the whole range of viral or bacterial or parasitic or other pathogens). Nasal swabs have the advantage of being relatively non-invasive. They also allow the simultaneous detection of a range of viral and other pathogens if needed.

In Hansen Disease (HD), the detection of asymptomatic cryptic LL is particularly important.

Many labs in endemic countries have been developing locally relevant versions. In India, the ICMR National Institute of Pathology, the ICMR JALMA Institute, the PGI medical and research institute (Chandigarh) and others are known to have their own versions. Technology institutes such as the IITs have developed low-cost supporting technology. Also labs in Brazil, China and elsewhere.

There is no need for HD to lag behind other diseases in the use of such user-friendly field technology. Partnership with a university / medical institute / lab will enable organizations of persons with lived experience to lead the charge against the bacillus.

Such technological breakthroughs keep shrinking the room for pessimism. The prospects of rapid progress grow.

With all sincerity,

Joel Almeida

                                               References

1.            T Notomi, H Okayama, H Masubuchi, T Yonekawa, K Watanabe, N Amino, T Hase.  Loop-mediated isothermal amplification of DNA  Nucleic Acids Res  2000 Jun 15;28(12):E63. doi: 10.1093/nar/28.12.e63.

2.            Joshi, S.; Dixit, K.K.; Sharma, V.; Ramesh, V.; Singh, R.; Salotra, P. Rapid Multiplex Loop-Mediated Isothermal Amplification (m-LAMP) Assay for Differential Diagnosis of Leprosy and Post–Kala-Azar Dermal Leishmaniasis. Am. J. Trop. Med. Hyg. 2021, 104, 2085–2090.  

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com


--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/d19d123f-eecb-43da-920f-23a16e7ac6a9n%40googlegroups.com.

Sunday, July 26, 2026

Fw: Ref.: (LML) First International CME Webinar of the IAL Academy | 29 July 2026 | Scientific Programme


 

Leprosy Mailing List –  July 26,  2026

 

Ref.:  (LML) First International CME Webinar of the IAL Academy | 29 July 2026 | Scientific Programme 

From: Sunil Dogra, Chandigarh,  India.

____________________________________________________________________________

Dear Colleagues/ IAL & ILA members / Leprosy Researchers/ ILEP Partners,

Greetings from the IAL!

It gives us immense pleasure to invite you to the First International CME Webinar of the IAL Academy, the academic arm of the Indian Association of Leprologists.

Theme:  Leprosy in 2026: Clinical Challenges & Emerging Horizons

Date: Wednesday, 29 July 2026
Time: 
7:00 PM IST onwards
 Platform: Zoom [Link attached - will become active 30 mins before scheduled time]
Meeting ID: 826 1623 4423
Passcode: IAL

This inaugural international webinar has been organized by the Clinical & Therapeutics Leprosy Focus Group of the IAL Academy and brings together a panel of eminent national and international experts. The programme features a keynote address by Dr Vishwa Mohan Katoch ) Former Secretary, DHR ( MoHFW, GoI) & DG, ICMR), renowned faculty including Prof. Ben Naafs (The Netherlands) and Dr Chathurarya Siriwardena & Dr Indira Kahawita (Sri Lanka), and an interactive panel discussion on therapeutic dilemmas in leprosy.

The webinar is designed for dermatologists, leprologists, physicians, postgraduate students, researchers, microbiologists, public health professionals, National & International Leprosy Programme personnel, physiotherapists, rehabilitation specialists, and all healthcare professionals involved in leprosy care.

Participation is free, and we encourage all members to actively participate and benefit from the latest evidence, expert insights, and practical clinical discussions. Webinar access details are available in the programme brochure.

The final scientific programme is attached for your reference.

We request you to circulate this announcement widely among your colleagues, departments, institutions, and postgraduate students so that the maximum number of healthcare professionals can benefit from this academic initiative.

We look forward to your enthusiastic participation in making this inaugural international webinar of the IAL Academy a grand success.

With warm regards,

--

Dr Sunil Dogra  

President    

Indian Association of Leprologists (IAL) 2026-2028

https://www.ial-leprosy.org        Email: ialoffice2026@gmail.com

Uploaded Image

---------- 

Sunil Dogra  

               MD, DNB. FAMS, FAAD, Dip Dermatology (Glasgow), FRCP (London), FRCP (Edinburgh)

Professor, Department of Dermatology, Venereology & Leprology

Postgraduate Institute of Medical Education & Research (PGIMER)

Chandigarh, 160012, India. I pgimer.edu.in I sundogra@hotmail.com  

 

____________________________________________________________________________

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << edit...@gmail.com


--
You received this message because you are subscribed to the Google Groups "Leprosy Mailing List" group.
To unsubscribe from this group and stop receiving emails from it, send an email to leprosymailinglist+unsubscribe@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/leprosymailinglist/ed95a7b4-5e2e-4d22-b51c-58ae5d63084dn%40googlegroups.com.